Prof Kjell Öberg discusses the development of new biomarkers which allow early detection of pNET and identify patients who are at high risk of recurrence after surgery and speaks about the superiority of molecular imaging with PET scan over traditional imaging technologies. Prof Öberg explains how he would interpret conflicting scan results and talks about everolimus, sunitinib and pasireotide, three promising new drugs for the treatment of advanced pNET.